CPX-351 improves survival in AML with myelodysplasia-related changes
New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
Case report describes myeloid sarcoma relapse in breast after nasal cavity presentation
A rare cancer returns to the breast six years after nasal treatment
This case report details the clinical course of a 68-year-old female with myeloid sarcoma and acute myeloid leukemia. The patient achieved c…
A rare blood cancer can hide in the breast for years and look exactly like a normal tumor without special lab tests
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Phase 1 trial of off-the-shelf NK cell therapy shows no DLTs or responses in relapsed/refractory AML
A Safer, Ready-to-Use Cell Therapy Takes Aim at Tough Leukemia
A single-arm, open-label, dose-escalation Phase 1 trial enrolled 6 adults with relapsed/refractory AML who received SAR445419, an off-the-sh…
A new, ready-to-use cell therapy proved safe in a first human trial for aggressive leukemia, offering hope for patients who have run out of …
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML
Adding Dasatinib to Chemo Does Not Help CBF-AML Patients
A phase 3 randomized trial in 202 adults with core-binding factor acute myeloid leukemia (CBF-AML) found adding dasatinib to intensive chemo…
Adding dasatinib to standard chemotherapy did not improve survival for adults with core-binding factor acute myeloid leukemia and increased …